What is the Oxaliplatin?

Oxaliplatin is White crystalline solid, while it's Molecular Formula is C8H14N2O4Pt. White crystalline solid A antitumor agent with activity against colorectal cancer. Cytotoxicity follows the formation of adducts with DNA

What is the CAS number for Oxaliplatin?

The CAS number of Oxaliplatin is 61825-94-3.

What is Oxaliplatin (61825-94-3) used for?

Eloxatin was launched in France for second-line treatment of metastaticcolorectal cancer. Oxaliplatin is a second generation platinum drug prepared in threesteps from either k2tCl4 or K2Ptl4. It has an antitumor spectrum similar to cisplatin,however, it is more effective against L1210 leukemia and cisplatin resistant L1210. Itis also effective against B16 melanoma but has a dose limiting toxicity of peripheralsensory neuropathy that is reversible upon cessation of the drug. The (R,R)-enantiomer has greater activity than the (S,S)-isomer but this is tumor linedependent, e.g., there was no difference found for P-388 or Sarcoma 180. Clinicaldrug administration based on circadium timing showed it was better tolerated whengiven 16 h after the onset of light. Oxaliplatin binds to guanineN7 and can lead tobidentate chelation that results in the bending of DNA. This feature is recognized byhigh mobility group proteins (HMG) which impedes repair reactions and stopsreplication and transcription.InChI:InChI=1/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1/rC8H14N2O4Pt/c11-7-8(12)14-15(13-7)9-5-3-1-2-4-6(5)10-15/h5-6H,1-4,9-10H2/t5-,6-/m1/s1

Product Class

61825-94-3

Product Name：Oxaliplatin
Molecular Formula：C₈H₁₄N₂O₄Pt
Purity：99%
Molecular Weight：397.29

Inquiry

Product Details:

CasNo： 61825-94-3

Molecular Formula： C₈H₁₄N₂O₄Pt

Appearance： White crystalline solid

Quality Manufacturer Supply Best Quality Oxaliplatin 61825-94-3 Efficient Transportation

Molecular Formula:C8H14N2O4Pt
Molecular Weight:397.29
Appearance/Colour:White crystalline solid
Boiling Point:193.6oC at 760 mmHg
Flash Point:75oC
PSA：104.64000
LogP:0.61450

Oxaliplatin(Cas 61825-94-3) Usage

Description	Oxaliplatin is a platinum-based chemotherapeutic agent used primarily to treat metastatic colorectal cancer. It belongs to a class of drugs known as DNA-crosslinking agents, which inhibit DNA synthesis in cancer cells by forming DNA-DNA and DNA-protein crosslinks, leading to cell death (apoptosis). It is commonly used in combination with other chemotherapy drugs.
Mechanism of Action	Oxaliplatin forms intrastrand and interstrand crosslinks within DNA, preventing DNA replication and transcription. This leads to cellular apoptosis, particularly in rapidly dividing cancer cells.
Originator	Bebiopharm (Switzerland)
Uses	Oxaliplatin is primarily used in the treatment of metastatic colorectal cancer. It is often part of combination chemotherapy regimens like FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin). Hangzhou Huarong Pharm Co., Ltd. established since 2009 , has been always focusing on supplying products and services to our clients in the field of small molecule drug. Huarong Pharm adheres to our vision, our mission, and our value, keeping abreast of the current trend and state-of-the-art science and technologies of the global biopharmaceutical industry to serve our clients to the utmost satisfaction. Our existing advantages have led to our in-depth services for the R&D of small molecule drug discovery.
Brand name	Eloxatin (Sanofi Aventis).
Administration	Oxaliplatin is administered intravenously, typically in combination with other chemotherapy agents. The dosage and treatment cycle depend on factors such as the patient's overall health, cancer stage, and other treatment considerations. Commonly, it is given once every two weeks as part of the FOLFOX regimen.

InChI:InChI=1/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1/rC8H14N2O4Pt/c11-7-8(12)14-15(13-7)9-5-3-1-2-4-6(5)10-15/h5-6H,1-4,9-10H2/t5-,6-/m1/s1

61825-94-3 Relevant articles

Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin

Robert A. Nagourney a , Steven Evans a , Peter H. Tran a , Adam J. Nagourney a , Paul H. Sugarbaker b

, European Journal of Surgical Oncology Volume 47, Issue 4 , April 2021, Pages 738-742

Of 87 fresh colon cancer specimens, 54 (62%) were untreated and 33 (38%) had received prior folinic acid, 5-fluorouracil, oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (CAPOX). The failure of PRODIGE 7 to improve survival with surgery plus HIPEC following NACT may reflect diminished oxaliplatin cytotoxicity in patients whose residual disease has been selected for oxaliplatin and 5-FU resistance.

Cellular and Molecular Pharmacology of Oxaliplatin

Eric Raymond; Sandrine Faivre; Stephen Chaney; Jan Woynarowski; Esteban Cvitkovic

, Mol Cancer Ther (2002) 1 (3): 227–235.

In in vivo studies, oxaliplatin is active against breast, colon, and gastric cancer; renal cell carcinoma; and sarcoma (16). In addition, oxaliplatin has been tested in vitro and in vivo against cisplatin-resistant cell lines and tumor models, including human ovarian, lung, cervix, colon, and leukemia cell lines.

Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development

Yang Yang, Bing Zhao, Xuejiao Gao, Jinbing Sun, Juan Ye, Jun Li & Peng Cao

Journal of Experimental & Clinical Cancer Research, Volume 40, article number 331, (2021)

Oxaliplatin (OHP)-induced peripheral neurotoxicity (OIPN) is a severe clinical problem and potentially permanent side effect of cancer treatment. For the management of OIPN, accurate diagnosis and understanding of significant risk factors including genetic vulnerability are essential to improve knowledge regarding the prevalence and incidence of OIPN as well as enhance strategies for the prevention and treatment of OIPN.

61825-94-3 Upstream products

61848-66-6
(1R,2R)-1,2-diaminocyclohexanedichloroplatinum(II)
33081-83-3
bis(tetrabutylammonium)oxalate
144-62-7
oxalic acid
583-52-8
potassium oxalate

61825-94-3 Downstream products

111263-58-2
cis-oxalic acid (trans-1,2-cyclohexanediamine)dihydroxyplatinum(II)
2864-70-2
5'-AGU-3'

Relevant Products

Tenofovir Disoproxil Fumarate
CAS：202138-50-9
Levofloxacin Hemihydrate
CAS：138199-71-0
Sparsentan
CAS：254740-64-2